COLL Q4 2023 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q4 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$150M+15.5% YoY

Gross Profit

$95M63.2% margin

Operating Income

$62M41.2% margin

Net Income

$32M21.3% margin

EPS (Diluted)

$0.82

QoQ Revenue Growth

+9.5%

Cash Flow

Operating Cash Flow

$73M

Free Cash Flow

$73M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$948M

Stockholders' Equity

$195M

Cash & Equivalents

$239M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$150M	$130M	+15.5%
Gross Profit	$95M	$50M	+90.1%
Operating Income	$62M	$12M	+424.7%
Net Income	$32M	-$7M	+543.7%

Revenue Segments

Belbuca

$95M33%

Xtampza ER

$88M31%

Nucynta IR

$52M18%

Nucynta ER

$42M15%

Symproic

$9M3%